AL amyloidosis associated with IgM monoclonal protein: A distinct clinical entity

Clinical Lymphoma and Myeloma

Volumn 9, Issue 1, 2009, Pages 80-83

  Palladini, Giovanni ^a   Russo, Paola ^a   Bosoni, Tiziana ^a   Sarais, Gabriele ^a   Lavatelli, Francesca ^a   Foli, Andrea ^a   Bragotti, Letizia Zenone ^a   Perfetti, Vittorio ^a   Obici, Laura ^a   Bergesio, Franco ^b   Albertini, Riccardo ^a   Moratti, Remigio ^a   Merlini, Giampaolo ^a  

^a UNIVERSITY OF PAVIA   (Italy)

^b CAREGGI UNIVERSITY HOSPITAL   (Italy)

Author keywords

Dexamethasone; Melphalan; Prednisone; Prognosis; Response; Waldenstr m; Waldenstr m's macroglobulinemia

Indexed keywords

BRAIN NATRIURETIC PEPTIDE; DEXAMETHASONE; IMMUNOGLOBULIN LIGHT CHAIN; IMMUNOGLOBULIN M; MELPHALAN; SERUM ALBUMIN; TROPONIN I;

ADULT; AGED; AMYLOIDOSIS; ARTICLE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; FEMALE; HUMAN; LYMPH NODE; MAJOR CLINICAL STUDY; MALE; PROTEINURIA; RARE DISEASE; REMISSION; TREATMENT RESPONSE; BLOOD; MIDDLE AGED; TREATMENT OUTCOME;

ADULT; AGED; AMYLOIDOSIS; FEMALE; HUMANS; IMMUNOGLOBULIN LIGHT CHAINS; IMMUNOGLOBULIN M; MALE; MIDDLE AGED; TREATMENT OUTCOME;

EID: 67649556687     PISSN: 15579190     EISSN: None     Source Type: Journal    
DOI: 10.3816/CLM.2009.n.021     Document Type: Article

References (15)

1. Merlini G, Stone MJ. Dangerous small B-cell clones. Blood 2006; 108:2520-30.
2. Merlini G, Palladini G. Amyloidosis: is a cure possible? Ann Oncol 2008; 19(suppl 4):iv63-6.
3. Kyle RA, Rajkumar SV. Monoclonal gammopathy of undetermined significance. Br J Haematol 2006; 134:573-9.
4. Gertz MA, Kyle RA, Noel P. Primary systemic amyloidosis: a rare complication of immunoglobulin M monoclonal gammopathies and Waldenstrom's macroglobulinemia. J Clin Oncol 1993; 11:914-20.
5. Terrier B, Jaccard A, Harousseau JL, et al. The clinical spectrum of IgM-related amyloidosis: a French nationwide retrospective study of 72 patients. Medicine (Baltimore) 2008; 87:99-109.
6. Wechalekar AD, Lachmann HJ, Goodman HJ, et al. AL amyloidosis associated with IgM paraproteinemia: clinical profile and treatment outcome. Blood 2008; 112:4009-16.
7. Arbustini E, Verga L, Concardi M, et al. Electron and immuno-electron microscopy of abdominal fat identifies and characterizes amyloid fibrils in suspected cardiac amyloidosis. Amyloid 2002; 9:108-14.
8. Gertz MA, Comenzo R, Falk RH, et al. Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): a consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis, Tours, France, 18-22 April 2004. Am J Hematol 2005; 79:319-28.
9. Palladini G, Perfetti V, Obici L, et al. Association of melphalan and high-dose dexamethasone is effective and well tolerated in patients with AL (primary) amyloidosis who are ineligible for stem cell transplantation. Blood 2004; 103:2936-8.
10. Dimopoulos MA, Anagnostopoulos A, Kyrtsonis MC, et al. Primary treatment of Waldenstrom macroglobulinemia with dexamethasone, rituximab, and cyclophosphamide. J Clin Oncol 2007; 25:3344-9.
11. Dispenzieri A, Lacy MQ, Katzmann JA, et al. Absolute values of immunoglobulin free light chains are prognostic in patients with primary systemic amyloidosis undergoing peripheral blood stem cell transplantation. Blood 2006; 107:3378-83.
12. Palladini G, Campana C, Klersy C, et al. Serum N-terminal pro-brain natriuretic peptide is a sensitive marker of myocardial dysfunction in AL amyloidosis. Circulation 2003; 107:2440-5.
13. Dispenzieri A, Gertz MA, Kyle RA, et al. Serum cardiac troponins and N-terminal pro-brain natriuretic peptide: a staging system for primary systemic amyloidosis. J Clin Oncol 2004; 22:3751-7.
14. Merlini G, Baldini L, Broglia C, et al. Prognostic factors in symptomatic Waldenstrom's macroglobulinemia. Semin Oncol 2003; 30:211-5.
15. Jaccard A, Moreau P, Leblond V, et al. High-dose melphalan versus melphalan plus dexamethasone for AL amyloidosis. N Engl J Med 2007; 357:1083-93.